相关实验视频

Updated: Jun 26, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

不同的COVID-19疫苗平台作为强剂的可互换性:3期研究模仿现实世界的实践

Sue Ann Costa Clemens¹, Lily Weckx², Eveline P Milan³

¹Institute for Global Health, University of Siena, Siena, Italy; Department of Pediatrics, Oxford University, Oxford, UK.

|May 18, 2024

概括

增剂COVID-19疫苗 (蛋白质,腺病毒载体,mRNA) 对成年人中的SARS-CoV-2变种安全有效. mRNA疫苗的初始免疫反应较高,但抗体减弱速度更快.

科学领域:

免疫学免疫学免疫学
疫苗学疫苗学疫苗学
传染性疾病传染性疾病

背景情况:

全球人口需要针对新出现的SARS-CoV-2变种进行持续的COVID-19强剂疫苗接种.
这项研究评估了巴西不同COVID-19疫苗增剂平台的安全性和免疫性.

研究的目的:

为了比较重组蛋白,腺病毒载体和mRNA COVID-19疫苗增剂的安全性和免疫性.
为了评估对祖先SARS-CoV-2和Omicron亚系的免疫反应.

主要方法:

第三阶段试验涉及先前免疫成年人,他们接受了三种疫苗平台之一的强剂量.
用ELISA IgG和病毒中和 (VNT) 抗体测量针对SARS-CoV-2变种的免疫性.
安全性和反应性通过日记卡进行评估.

主要成果:

所有的疫苗助推剂都能很好地耐受,具有相似的反应性特征.
所有组的抗体标位都增加,与蛋白质 (SCB-2019) 或腺病毒载体 (ChAdOx1-S) 相比,对mRNA (BNT162b2) 的初始反应更高.
接种mRNA疫苗的人在接种疫苗后84天显示出更快的抗体减弱.

结论:

蛋白质,腺病毒载体和mRNACOVID-19疫苗增强剂在完全免疫的成年人中对SARS-CoV-2变种是安全的和免疫的.
mRNA增强剂引起最强的初始免疫反应,但与更快的抗体衰减有关.
增强剂的选择可能取决于平衡峰值免疫性与响应持续时间.

关键词:

蛋白质疫苗是一种蛋白质疫苗.这就是SARS-CoV-2病毒.病毒载体疫苗疫苗疫苗这是mRNA疫苗.

更多相关视频

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Author Spotlight: Advancing Immune Monitoring in Critical Care Patients Using Whole Blood Assays

Published on: September 20, 2024

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers

An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

相关概念视频

Bioequivalence: Overview

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...

Vaccinations

Vaccinations

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Cross-reactivity

Cross-reactivity